HighlightsThird quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on ...

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $22.1 million in its third quarter. On a per-share basis, the Salt Lake City-based company said ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

On Monday, TD Cowen maintained a Hold rating for Myriad Genetics (NASDAQ:MYGN) shares with a steady price target of $30.00. This decision comes in the wake of UnitedHealthcare's (UNH) recent ...

On Friday, Myriad Genetics, Inc. (MYGN) stock saw a decline, ending the day at $17.99 which represents a decrease of $-3.97 or -18.08% from the prior close of $21.96. The stock opened at $20.04 and ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...

Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer cover the company's genetic test that helps to determine which mental ...

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...

(MENAFN- GlobeNewsWire - Nasdaq) SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on ...